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result of selective pressure from the increased use of fluoroqui-
nolones [4].
Finally, a balance between efficacy and toxicity must enter
into the consideration of selection of any antimicrobial agent. In
spite of good in vitro activity, grepafloxacin, sparfloxacin, tema-
floxacin and trovafloxacin have had toxicities arise that have
either severely limited these agents or completely eliminated
them from clinical consideration.
As shown by previous studies with smaller number of isolates,
BMS 284756 demonstrated greater in vitro potency when
compared to other fluoroquinolones. This study extends the
observations from studies in Japan by including a larger number
of isolates as well as comparative agents [1].
In summary, whereas all the new fluoroquinolones tested in
this study demonstrated enhanced in vitro activity compared to
ciprofloxacin and levofloxacin, BMS 284756 demonstrated the
greatest in vitro activity.
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Fatal Roseomonas gilardii bacteremia in a patient with refractory
blast crisis of chronicmyeloid leukemia
In January 2000, a 31-year-old male with refractory blast crisis
of chronic myeloid leukemia (CML) since July 1998 attended
the hematology clinic with fever and productive cough,
3 months following implantation of a Hickman catheter.
Although chemotherapy had achieved morphologic remission,
cytogenetic studies showed an approximate 50% positivity for
the Philadelphia chromosome, and in October 1999, bone
marrow aspirate revealed residual leukemia with 30% blasts.
Owing to the refractory nature of this disease and the con-
sequent poor prognosis for recovery, the patient was managed
symptomatically and with palliative chemotherapy.
On examination, the patient was pale and lethargic, with a
temperature of 40.5 8C, a tachycardia of 120 beats/min, and a
blood pressure of 140/90 mmHg. Chest auscultation revealed
diffuse expiratory wheeze and crepitations at the right base. The
abdomen was tense but non-tender. The patient was admitted
and started empirically on piperacillin–tazobactam 4.5 g
8-hourly and gentamicin 7.5 mg/kg per day. Shortly after the
first dose of gentamicin, he developed severe abdominal pain
which was attributed to gentamicin, which was then substituted
with vancomycin 1 g 12-hourly. On admission, the total leu-
kocyte count was 11.1 109/L, and the neutrophil count was
2.94 109/L. During the preceding year, typical values for total
leukocyte count were <2.5 109/L, and those for the neu-
trophil count were<0.5 109/L. Blood culture sets, from both
Hickman and peripheral lines, were positive for Gram-negative
bacilli after 4 days of incubation (BacTAlert, Organon-Teknika,
Boxtel, the Netherlands). As the pyrexia was unresponsive to
piperacillin–tazobactam, this was substituted with ceftazidime
2 g 8-hourly on day 3, which led to rapid resolution. Further
blood cultures drawn from the Hickman line on day 3 following
admission grew a similar organism. Vancomycin and ceftazi-
dime were continued for a total of 5 days, after which the patient
was discharged home on oral ciprofloxacin and clarithromycin
for his residual chest infection. One week later he presented in
the outpatient department with a low-grade pyrexia and per-
sistent non-productive cough. Blood cultures drawn from the
Hickman line at this time again grew a Gram-negative bacillus
after 4 days of incubation. However, following routine blood
and platelet transfusion, the patient refused further intervention
and was discharged home. Two weeks later he died, following a
pyrexial episode.
On all three occasions, subculture of blood culture fluid
revealed pink-pigmented colonies which grew after 48 h of
incubation at 37 8C on Columbia blood agar plates. These
organisms were Gram-negative bacilli, arranged in pairs, which
grew on MacConkey agar, and were positive for catalase and
oxidase. The isolates gave positive reactions for urea hydrolysis
and oxidation of glucose, arabinose and citrate. However, the
isolates tested negative for nitrate reduction, indole production,
arginine dehydrolase, gelatinase and b-galactosidase. The iso-
lates were also negative for oxidation of mannose, maltose,
mannitol and N-acetylglucosamine (API 20E and API 20NE
biochemical strip, BioMe´rieux, La Balme-Les-Grottes, France).
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Long-chain cellular fatty acid analysis using the Microbial
Identification System (MIDI Inc., Newark, DE, USA)
confirmed the identity of the isolates as Roseomonas gilardii.
By E test (AB Biodisk, Solna, Sweden), all three isolates were
uniformly susceptible to gentamicin (MIC¼ 0.125 mg/L),
amikacin (MIC¼ 1 mg/L), imipenem (MIC¼ 1 mg/L), mero-
penem (MIC¼ 0.25 mg/L), co-trimoxazole (MIC¼ 1 mg/L),
and minocycyline (MIC¼ 2 mg/L), and resistant to ceftazidime
(MIC> 256 mg/L), piperacillin (MIC> 256 mg/L), pipe-
racillin–tazobactam (MIC> 256 mg/L), ticarcillin (MIC>
256 mg/L), and ticarcillin–clavulanate (MIC> 16 mg/L). A
disk diffusion method indicated resistance to ciprofloxacin,
although the MIC of ciprofloxacin was not determined. No
increase in the MICs was observed following antibiotic therapy.
The three isolates were indistinguishable by pulsed-field gel
electrophoresis of XbaI chromosomal DNA digests.
Roseomonas is a newly proposed genus comprising pink-
pigmented, Gram-negative coccobacilli which possess oxidative
metabolism. The genus includes three named species, R. gilardii,
R. cervicalis and R. fauriae, and three unnamed genomospecies
[1]. Although a few strains have been isolated from various
environmental sources, such as potable water, saline contami-
nant and plastic ice balls [1,2], the natural reservoir for Roseo-
monas spp. is unknown. Although most isolations are from blood
culture [3–7], the organism has also been isolated from wounds,
exudates, abscesses and genitourinary specimens [1,8–10]. In
addition, infection has been associated with peritonitis com-
plicating continuous ambulatory peritoneal dialysis (CAPD)
[11,12] and vertebral osteomyelitis [13]. However, the clinical
significance of these isolates is not always clear, and in one
review of 35 cases from which Roseomonas strains were isolated,
only 60% were associated with disease [10]. Infection usually
occurs in patients with underlying medical illness such as malig-
nancy, acquired immune deficiency syndrome (AIDS), chronic
renal disease or diabetes mellitus [14]. Unfortunately, bacter-
emia in the present case was not unequivocally linked with the
presence of the Hickman line, in that further tests were not
performed. However, the Hickman line would appear to be the
most likely focus of infection in the absence of another identi-
fied focus of infection, as the organism grew from blood
cultures taken from the line, and in view of previous reports
[6,15].
In the present case, the time taken for the organism to be
detected in blood culture (4 days) combined with the time taken
for growth on solid media following subculture (48 h) pre-
cluded the institution of specific antimicrobial therapy for this
infection. Despite the use of piperacillin–tazobactam and cef-
tazidime, which both had MICs of>256 mg/L for the causative
organism, there was an apparent clinical resolution. However,
this infection recurred while on ciprofloxacin (to which the
organism was resistant by disk diffusion testing) and as the
patient refused further intervention, the infection was managed
without antibiotic therapy. The patient died 2 weeks following
this recurrence.
In conclusion, we present a case of infection with R. gilardii
sp. nov. which, due to its slow growth and the patient’s refusal of
further medical intervention, resulted in his death 5 weeks
following the first isolation of the organism from blood
culture. This report underlines the pathogenic potential of this
organism, and it should be considered of possible clinical
significance, particularly in the presence of an indwelling
vascular device [6,15].
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